Media stories about Co-Diagnostics (NASDAQ:CODX) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern scores the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Co-Diagnostics earned a news impact score of 0.07 on Accern’s scale. Accern also gave media headlines about the company an impact score of 44.6258323343634 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Co-Diagnostics (NASDAQ CODX) traded down 1.96% during trading on Friday, reaching $5.50. The company had a trading volume of 33,446 shares. Co-Diagnostics has a 12 month low of $3.50 and a 12 month high of $6.24. The firm’s 50 day moving average is $4.83 and its 200-day moving average is $5.52. The company’s market capitalization is $65.55 million.
ILLEGAL ACTIVITY NOTICE: This piece of content was first published by BBNS and is owned by of BBNS. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://baseballnewssource.com/markets/co-diagnostics-codx-earns-daily-media-impact-rating-of-0-07/1565370.html.
Co-Diagnostics, Inc is a molecular diagnostics company. The Company is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid.
Receive News & Ratings for Co-Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics Inc and related companies with our FREE daily email newsletter.